Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

William F. Regine

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5070621756. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
72
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: 3 papers · 2015: 1 paper · 2016: 3 papers · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 20

  1. High SMAD4 Expression is Associated With Improved Clinical Outcomes in Patients With Resectable Pancreatic Cancer: An Analysis of NRG Oncology/RTOG 9704. Co-author DOI 10.1016/j.ijrobp.2026.09.014↗
  2. Proton Therapy for Unresectable and Medically Inoperable Locally Advanced Pancreatic Cancer: Results From a Multi-Institutional Prospective Registry. Co-author DOI 10.1016/j.adro.2023.101250↗
  3. Pancreatic cancer derived 3D organoids as a clinical tool to evaluate the treatment response. Co-author DOI 10.3389/fonc.2022.1072774↗
  4. Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. Co-author DOI 10.1016/j.ijrobp.2020.08.042↗
  5. Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. Co-author DOI 10.1634/theoncologist.2019-0562↗
  6. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Co-author DOI 10.1016/j.tranon.2018.08.017↗
  7. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. Co-author DOI 10.1186/s12885-019-5790-2↗
  8. Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG … Co-author DOI 10.1002/cncr.31058↗
  9. Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer. Co-author DOI 10.21037/jgo.2018.03.14↗
  10. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Co-author DOI 10.1016/j.soc.2017.01.012↗
  11. Does lymphocyte-to-monocyte ratio before, during, or after definitive chemoradiation for locally advanced pancreatic cancer predict for clinical outcomes? Co-author DOI 10.21037/jgo.2017.06.14↗
  12. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy… Co-author DOI 10.1016/j.ijrobp.2015.10.062↗
  13. Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach. Co-author DOI 10.1097/mpa.0000000000000710↗
  14. Individually optimized contrast-enhanced 4D-CT for radiotherapy simulation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1118/1.4963213↗
  15. Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (≥75 years) Patients. Co-author PMID 26026108↗
  16. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2014.07.024↗
  17. Utilization of intensity-modulated radiation therapy and image-guided radiation therapy in pancreatic cancer: is it beneficial? Last author DOI 10.1016/j.semradonc.2013.11.003↗
  18. Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us? Last author DOI 10.3978/j.issn.2078-6891.2014.025↗
  19. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for panc… Co-author DOI 10.1016/j.ijrobp.2010.07.1993↗
  20. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S… Co-author DOI 10.1245/s10434-011-1630-6↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chandan Guha · 4 shared papers, 2016–2026 · strength 0.41
  2. Joseph M. Herman · 5 shared papers, 2014–2023 · strength 0.35
  3. Edgar Ben‐Josef · 2 shared papers, 2020–2026 · strength 0.32
  4. Michael G. Haddock · 2 shared papers, 2020–2026 · strength 0.32
  5. Michael David Chuong · 4 shared papers, 2014–2018 · strength 0.31
  6. Christopher H. Crane · 4 shared papers, 2016–2021 · strength 0.31
  7. John Parker Hoffman · 5 shared papers, 2011–2021 · strength 0.29
  8. Ross Allen Abrams · 5 shared papers, 2011–2021 · strength 0.29
  9. Howard P. Safran · 5 shared papers, 2011–2021 · strength 0.29
  10. Hyun Kim · 1 shared paper, 2026 · strength 0.24
  11. Ryan N. Robb · 1 shared paper, 2026 · strength 0.24
  12. Terence Marques Williams · 1 shared paper, 2026 · strength 0.24
  13. Lauren E. Henke · 1 shared paper, 2026 · strength 0.24
  14. Jason K. Molitoris · 2 shared papers, 2017–2022 · strength 0.23
  15. Romaine Charles Nichols · 2 shared papers, 2018–2023 · strength 0.21
  16. Gian Carlo Mattiucci · 4 shared papers, 2014–2019 · strength 0.21
  17. Felipe Ángel Calvo · 4 shared papers, 2014–2019 · strength 0.21
  18. Robert Clell Miller · 4 shared papers, 2014–2019 · strength 0.21
  19. Alessio Giuseppe Morganti · 4 shared papers, 2014–2019 · strength 0.21
  20. Sergio Alfieri · 4 shared papers, 2014–2019 · strength 0.21
  21. Vincenzo Valentini · 4 shared papers, 2014–2019 · strength 0.21
  22. Massimo Falconi · 4 shared papers, 2014–2019 · strength 0.21
  23. Michele Reni · 4 shared papers, 2014–2019 · strength 0.21
  24. Al B. Benson · 4 shared papers, 2011–2021 · strength 0.21
  25. Shahed Nicolas Badiyan · 2 shared papers, 2017–2018 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.